Bayesian Trial Submissions Could Consume More FDA Resources, CDRH Says
This article was originally published in The Pink Sheet Daily
Device center statisticians currently spend at most 5%-10% of their time and effort evaluating Bayesian statistical analyses in premarket submissions, but the center continues to ramp up its resources to deal with a potential influx relying on the advanced technique.
You may also be interested in...
The high-profile COURAGE trial again raises the question of how soon stents should be placed in patients with coronary disease.
NIH and government agencies plan to submit plans to Congress next month describing ways to encourage the development of medical devices for children.
Do not be cavalier about this venue, drug/device lawyer warns.